Nymox Pharmaceutical Corp (NASDAQ:NYMX)

CAPS Rating: 1 out of 5

A biopharmaceutical company with three proprietary products on the market and a R&D of drug & diagnostic products in development for the treatment of enlarged prostate, Alzheimer's disease contamination of food and drink products and bacterial infections.


Player Avatar zzlangerhans (99.85) Submitted: 12/3/2012 6:52:43 PM : Underperform Start Price: $7.35 NYMX Score: +12.93

Nymox stock is flip-flopping all over the place ahead of phase III data for NX-1207 in BPH and I think this might be a good options play as there's very little hype about this major catalyst, which has kept premiums relatively low. The share price will probably go sub-1 with failure, and could double with success. The problem is that the company releases so little information that it is difficult to determine when topline data will be released. After I had interpreted prior PR to indicate a 2012 data release, it now appears that topline data from NX02-0017 won't be released until late 2013. Four years for a BPH trial seems a little excessive to me, and I'd give 70% odds this trial will be a failure.

Featured Broker Partners